Home Featured Page 12

Featured

Latest

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant...

Field Notes #2: Dispatches from London and the Netherlands

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA...

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

Pα+ Psychedelic Bulletin #234: Psychedelics After the Midterms; FDA Answers House Psychedelics Caucus; ICER to Review Compass’ Psilocybin; Terran v. Compass Gets Trial Date

Is It Worth It? What Colorado’s Early Experience With Regulated Psychedelic Care Has the Field Asking, and What To Do About It

Psilocybin Compassionate Use in Germany: Lea Mertens and Andrea Jungaberle on...

Out of This World: Why AI Belongs Beside the Therapist

Shroomski Melt

Psychedelic Policy Briefing: June 11, 2026

May 2026 Psychedelic Bill Roundup

Utah’s Quiet Revolution: Why HB 390 May Be the Most Significant...

Field Notes #2: Dispatches from London and the Netherlands

Pα+ Psychedelic Bulletin #225: Q1 Lobbying Update; Individual vs. Group MDMA...

Three Brain Injuries, One Iboga Protocol, and What It Tells Us

The War on Drugs Was Never About Drugs. Psychedelic Healing Must...

EDITOR PICKS

Robert Rush: Emergency Scheduling, 7-OH, and the War on Research

Breaking: Compass Files Psilocybin for TRD New Drug Application with FDA

The Problems We Will Be Lucky to Have

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY